Health-Related Quality of Life (HRQoL) Reporting in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Risk Stratified by Multiparametric MRI (mpMRI)
Author(s)
Marika French, MSc1, Michael Ndaa, MSc1, Elizabeth Shumbayawonda, PhD1, Hildo Lamb, MD, PhD2.
1Perspectum, Oxford, United Kingdom, 2Leiden University, Leiden, Netherlands.
1Perspectum, Oxford, United Kingdom, 2Leiden University, Leiden, Netherlands.
OBJECTIVES: The prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide and is expected to have a prevalence of 55% by 2040. Metabolic dysfunction-associated steatohepatitis (MASH), a more serious form of MASLD, is expected to have a US prevalence of 5% by 2040. While the clinical outcomes are well understood, there is limited data on Health-Related Quality of Life (HRQoL) in MASH. Such data is important for evaluation the disease burden and guiding clinical decision-making. This research aimed to identify the characteristics of HRQoL among MASH patients. The comparison was based on liver disease activity, assessed through multiparametric MRI (mpMRI), using corrected T1 (cT1) to characterise liver disease activity and Proton Density Fat Fraction (PDFF) for liver fat.
METHODS: 802 (female: 349, male: 453) patients with MASLD/MASH were recruited from specialist centres in Germany, the Netherlands, Portugal and the UK. Each participant completed EQ-5D-5L and VAS questionnaires across four time-points (baseline, 2-months, 6-months and 12-months). In this study, MASH was defined as cT1 ≥800ms and PDFF ≥10%.
RESULTS: Compared to those with MASLD, MASH patients showed worse self-reported scores across all dimensions of the EQ-5D-5L and VAS and were 15% more likely to report pain/discomfort. After adjusting for comorbidities (obesity, age, diabetes and hyperlipidaemia) MASH patients still showed poorer scores across all EQ-5D dimensions. Among patients with obesity, those with MASH were 35% more likely to report pain/discomfort compared to those with MASLD. Females reporting lower scores across all dimensions with the biggest discrepancy in pain/discomfort, where females were 21% more likely to report problems than males.
CONCLUSIONS: Abnormal mpMRI metrics were an indicator of poorer Health-Related Quality of Life in MASH patients, especially for pain/discomfort. MASLD/MASH management should consider integrating both patient-reported outcomes and mpMRI alongside current tools in standard-of-care to inform clinical decisions.
METHODS: 802 (female: 349, male: 453) patients with MASLD/MASH were recruited from specialist centres in Germany, the Netherlands, Portugal and the UK. Each participant completed EQ-5D-5L and VAS questionnaires across four time-points (baseline, 2-months, 6-months and 12-months). In this study, MASH was defined as cT1 ≥800ms and PDFF ≥10%.
RESULTS: Compared to those with MASLD, MASH patients showed worse self-reported scores across all dimensions of the EQ-5D-5L and VAS and were 15% more likely to report pain/discomfort. After adjusting for comorbidities (obesity, age, diabetes and hyperlipidaemia) MASH patients still showed poorer scores across all EQ-5D dimensions. Among patients with obesity, those with MASH were 35% more likely to report pain/discomfort compared to those with MASLD. Females reporting lower scores across all dimensions with the biggest discrepancy in pain/discomfort, where females were 21% more likely to report problems than males.
CONCLUSIONS: Abnormal mpMRI metrics were an indicator of poorer Health-Related Quality of Life in MASH patients, especially for pain/discomfort. MASLD/MASH management should consider integrating both patient-reported outcomes and mpMRI alongside current tools in standard-of-care to inform clinical decisions.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
PCR106
Topic
Economic Evaluation, Medical Technologies, Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), Gastrointestinal Disorders